# Gynecologic Oncology Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Gilda Radner (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML026-SYN-TD
- Date: 1986-04-14
- Fictional facility: St. Posthumous Health Center
- Fictional author: Sunita Varghese, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Requested by: Delia Marchand, MD

## Reason for consultation

Suspected ovarian cancer in a 39-year-old comedian and actor with four weeks of bloating, early fullness, pelvic pain and urinary frequency on most days (ovarian cancer symptom index positive), a firm, fixed right adnexal mass and ascites on examination, a CA-125 of 1240 U/mL, and ovarian cancer in three relatives. Please see her within the week, confirm the diagnosis, and plan her primary treatment. **S**

## History

Ms. Radner, 39, is seen at the request of Dr. Marchand eight days after she first described four weeks of bloating, early fullness, pelvic pain and urinary frequency. Ultrasound the next day, CT the day after, and an omental core biopsy two days later have been completed. She eats small meals without vomiting and her bowels move daily. She has not carried a pregnancy to term and is not trying to conceive. Ovarian cancer affected her grandmother, an aunt and a cousin; she is of Ashkenazi Jewish ancestry. She is active and working, and she wants the facts and the plan plainly. **S**

## Examination

| System | Finding |
|---|---|
| General | Tired but composed; weight 58.9 kg; blood pressure 122/78, pulse 96 |
| Abdomen | Distended with shifting dullness; firm upper abdominal fullness consistent with omental disease; non-tender |
| Pelvic | Fixed, irregular masses in both adnexa, larger on the right; cervix normal; no rectovaginal nodularity |
| Lymph nodes | No supraclavicular, axillary or inguinal nodes |

BP 122/78 mmHg; pulse 96 bpm; respirations 16/min; temperature 36.8 °C; oxygen saturation 98% on room air; weight 58.9 kg; BMI 23 kg/m². All vital signs are synthetic.

## Data reviewed

Dr. Marchand's intake note. CA-125 1240 U/mL and CEA 1.6 ng/mL. Transvaginal ultrasound: a 9.2 cm solid and cystic right adnexal mass and a 5.1 cm solid left adnexal mass with internal blood flow, and moderate ascites (O-RADS 5). CT of the chest, abdomen and pelvis: bilateral adnexal masses, moderate ascites, omental caking up to 4 cm, a 1.2 cm right hemidiaphragm nodule and small pelvic peritoneal nodules; no enlarged lymph nodes, no liver or lung lesion, no pleural effusion. Omental core biopsy: high-grade serous carcinoma, PAX8 and WT1 positive, p53 aberrant, CK7 positive and CK20 negative. Hemoglobin 12.4 g/dL, platelets 412, creatinine 0.72 mg/dL, albumin 3.6 g/dL. PHQ-9: 7; GAD-7: 8. All results are synthetic.

## Assessment

1. **High-grade serous carcinoma of both ovaries, clinical FIGO stage IIIC** (C56.3). The biopsy and imaging establish high-grade serous carcinoma of Mullerian origin, clinical FIGO stage IIIC: disease in both ovaries, the omentum, the pelvic peritoneum and the right diaphragm, with no disease in the liver parenchyma, lungs or lymph nodes and no pleural effusion. She is fit, and the pattern of disease on CT can probably be removed completely, so primary cytoreductive surgery is preferred over chemotherapy first; the aim is no visible residual disease, which carries the best outlook. Surgery will be a laparotomy with hysterectomy, removal of both tubes and ovaries, total omentectomy, and removal of all visible peritoneal and diaphragmatic disease; lymph nodes will be removed only if enlarged. Pregnancy is not possible after this operation, which we discussed gently. Every woman with epithelial ovarian cancer should have germline genetic testing with counseling, and the tumor should be tested for BRCA1 and BRCA2 and homologous recombination deficiency, because the results guide maintenance treatment and, if a germline variant is found, testing for her blood relatives. Six cycles of carboplatin and paclitaxel every three weeks follow surgery; maintenance after a response is chosen from the genetic results, with a PARP inhibitor preferred if a BRCA1 or BRCA2 variant is found in the blood or the tumor; bevacizumab is not planned if all visible disease is removed. **S**
2. **Family history of ovarian cancer** (Z80.41). Three relatives with ovarian cancer and Ashkenazi Jewish ancestry raise the chance of an inherited variant. A negative result in her would not end the need for advice for her relatives, since none of the affected relatives was tested. **S**

## Recommendations

1. Primary cytoreductive surgery in one week, aiming for no visible residual disease.
2. Genetic counseling and a germline multigene panel today (BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 and the Lynch syndrome genes); tumor testing for BRCA1 and BRCA2 and homologous recombination deficiency on the surgical specimen; a family letter offering cascade testing to blood relatives if a germline variant is found.
3. Hepatitis B, hepatitis C and HIV screening before chemotherapy.
4. Carboplatin AUC 5 and paclitaxel 175 mg/m2 every 21 days for six cycles, starting about three weeks after surgery, with a three-drug antiemetic regimen; blood counts, kidney function and magnesium before each cycle; CA-125 before each cycle; neuropathy checks before each paclitaxel dose; CT at the end of treatment.
5. Maintenance after a complete or partial response chosen from the genetic results: olaparib for two years if a BRCA1 or BRCA2 variant is found in the blood or tumor, with a monthly blood count.
6. Enoxaparin 40 mg daily for four weeks after surgery.
7. Distress screening at each visit, a cancer support community group, plain written information, and a discussion of surgical menopause and its management after the operation.

## Strengths and supports

- Supports: her spouse and close friends from work; humor is how she copes. She decides who is told about her health **S**

## Communication

Discussed with Dr. Marchand, who saw her the same day. The images and biopsy were explained to Ms. Radner, who chose surgery next week; she decides who else receives this note. **S**

## Follow-up

Surgery in one week; gynecologic oncology review after the pathology and before each cycle; Dr. Marchand continues primary care and shares the monitoring. **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 4.2026 (2026), National Comprehensive Cancer Network
- Konstantinopoulos PA, et al. Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline. J Clin Oncol 2020;38(11):1222-1245 (2020), American Society of Clinical Oncology
- Tew WP, et al. PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline. J Clin Oncol 2020;38(30):3468-3493 (2020), American Society of Clinical Oncology
- Key NS, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2023;41(16):3063-3071 (2023), American Society of Clinical Oncology
- Hesketh PJ, et al. Antiemetics: ASCO Guideline Update. J Clin Oncol 2020;38(24):2782-2797 (2020), American Society of Clinical Oncology
- Hwang JP, et al. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update. J Clin Oncol 2020 (2020), American Society of Clinical Oncology
